Long-term outcomes of transcatheter mitral valve repair in patients with cancer: a systematic review and meta-analysis.

Filippo Biondi, Christian Cadeddu, Massimiliano Camilli, Alessandra Cuomo, Giulia Elena Mandoli, Andrea Minghini, Giuseppina Novo, Rosalinda Madonna

Abstract read

PubMed Publisher

In one paragraph

Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Filippo BiondiDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.

Christian CadedduDepartment of Medical Sciences and Public Health, Cardiology Unit, University Hospital Duilio Casula-Azienda Ospedaliero, University of Cagliari, Cagliari, Italy.

Massimiliano CamilliDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.

Alessandra CuomoDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Giulia Elena MandoliDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.

Andrea MinghiniDepartment of Internal Medicine, University of Genova, Viale Benedetto XV, 6, Genoa, 16132, Italy.

Giuseppina NovoDepartment of Health Promotion, Mother and Child Care Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.

Rosalinda MadonnaDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy. rosalinda.madonna@unipi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical and transcatheter mitral valve interventions are the mainstay of treatment for mitral regurgitation (MR). Their impact in patients with cancer has recently gained attention in observational studies but remains poorly characterized. We performed a systematic review and meta-analysis to evaluate outcomes of mitral valve interventions, with particular focus on M-TEER, in patients with active or prior cancer. PubMed and Scopus were systematically searched according to the PRISMA 2020 Statement. This systematic review was prospectively registered in PROSPERO (CRD420261368392). Studies reporting outcomes of transcatheter or surgical mitral valve interventions in patients with cancer were eligible. The primary outcome was all-cause mortality. Secondary outcomes included short-term mortality, procedural success, heart failure worsening or hospitalization, and reintervention. Hazard ratios (HRs) were pooled using random-effects models when appropriate. When HRs were not directly available, they were reconstructed according to established methods for time-to-event data synthesis. Eight observational studies met the inclusion criteria. Seven studies evaluated M-TEER, accounting for the vast majority of patients included in the quantitative analyses (1522 patients with cancer and 4716 controls), whereas only one study assessed surgical mitral valve intervention. In the pooled analysis of M-TEER studies, cancer was associated with a significantly higher risk of all-cause mortality during follow-up (HR 1.72, 95% CI 1.03-2.90; I

Indexed as

Cancer patientsCardio-oncologyMeta-analysisMitral regurgitationMitral valve interventionsTranscatheter mitral valve repair

Identifiers

PMID42786380

DOI10.1093/EJCTS/EZAA403

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.